Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

NCT04115761 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

GBM

Interventions

BIOLOGICAL: autologous dendritic cells

Sponsor

Ever Supreme Bio Technology Co., Ltd.